UnitedHealth Group (UNH) received a 77% rating from Validea's Martin Zweig Growth Investor model, placing it just below the 80% threshold for 'some interest' according to the strategy. While UNH passes several key growth and valuation metrics, including long-term EPS growth and current quarter earnings, the analysis flagged concerns regarding its revenue growth in relation to EPS growth and the consistency of its earnings growth over recent quarters.
UnitedHealth Group (UNH) registers a 77% rating from Validea's Martin Zweig-based Growth Investor model, placing it just under the 80% threshold that indicates initial interest from the strategy. The analysis presents a mixed but moderately positive fundamental picture. On the positive side, UNH meets the criteria for a reasonable P/E ratio, solid sales growth, and positive current quarter earnings performance both on a standalone and year-over-year basis. The model also affirms the company's long-term EPS growth trajectory, earnings persistence, and indicates no concerns regarding insider selling. However, the quantitative screen also flags several material weaknesses that temper the outlook. Specifically, UNH fails on the metric comparing revenue growth to EPS growth, which can suggest that bottom-line gains are not fully supported by top-line expansion. Furthermore, the model identifies a lack of consistent earnings acceleration, noting a failure in the earnings growth rate over the past several quarters and that current EPS growth does not exceed the firm's own historical growth rate, pointing to a potential deceleration in momentum.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
